Biokin Pharmaceutical Selects Cryoport's Temperature-Controlled Solutions for its Pending Phase I and Phase II trials

CHENGDU,China andSEATTLE and IRVINE,California,March 28,2019 --Biokin Pharmaceutical Co. Ltd.,("Biokin Pharma") a leading pharmaceutical company with operations in China and U.S.,and Cryoport,Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport"),the world's leading temperature-controlled logistics company dedicated to the life sciences industry,today announced Cryoport's full suite of temperature-controlled solutions will support Biokin Pharma's pending Phase I and II clinical trials in immuno-oncology in both the U.S. and China.

Biokin Pharma,is a biopharmaceutical company based in China focused on the treatment of cancer through developing novel therapeutic antibodies and antibody-drug conjugates ("ADC"s). Led by a group of highly experienced immuno-oncology scientists,the company utilizes several technology platforms to develop world class advanced antibody-based drug therapies. Its wholly-owned subsidiary SystImmune Inc. ("SystImmune"),which is funded in part by OrbiMed,was formed to advance its mission in the United States. Partnering with Cryoport will enable Biokin Pharma and SystImmune to utilize Cryoport's full range of temperature-controlled logistics solutions to support its drug manufacturing processes across the globe. These solutions include the Cryoport Express® shippers,the industry-leading Cryoportal™ Logistics Management Platform,Smartpak II™ Condition Monitoring System and 24/7/365 logistics support.

"We are pleased to choose the highly reliable condition- and time-sensitive logistics solutions provided by Cryoport to support our upcoming clinical studies using Bispecific and Multi-specific Antibody,ADC,and T-cell Therapy," said Dr. Yi Zhu,Chairman of Biokin Pharma and its U.S. subsidiary,Systimmune of Seattle,WA. "By relying on Cryoport's excellent solutions,Biokin Pharma and Systimmune will continue to have the best possible viability and recovery of critical cells,vectors,antibodies and other materials,even after time-consuming international or domestic transportation,to ensure the best outcome for our patients."

"As the regenerative medicine market rapidly matures,the demand for our technology-driven solutions to support trials across the globe is growing. We look forward to working alongside Biokin Pharma and its U.S. subsidiary to ensure reliable,secure logistics support for their temperature-sensitive commodities as they advance the development of potentially life-saving therapies," said Mark Sawicki,PhD,Chief Commercial Officer of Cryoport.

About Biokin Pharma

Biokin Pharma researches and develops innovative therapies in immuno-oncology for cancer patients worldwide using targeted antibody,and cell therapy.For 2019 to 2020,Biokin expects to start four clinical trials in the U.S. and China using its SI-B001,SI-B003/032,GNC-038/039 therapies.One of the industry's leading biopharma companies,Biokin Pharma was founded in 1996 by Dr. Yi Zhu with GMP R&D and manufacturing facilities in China and a US subsidiary- Systimmune Inc in Seattle WA.Biokin and Systimmune today have a leading portfolio of medicines targeting Epithelial Tumor,Non-small cell lung cancer,blood cancer,solid tumor,and other indications.

For more information,visit http://www.baili-pharm.com or http://www.systimmune.com.

About Cryoport,Inc.

Cryoport is the life sciences industry's most trusted global provider of temperature-controlled logistics solutions for temperature-sensitive life sciences commodities,serving the biopharmaceutical market with leading-edge logistics solutions for biologic materials,such as regenerative medicine,including immunotherapies,stem cells and CAR T-cells. Cryoport's solutions are used by points-of-care,CRO's,central laboratories,pharmaceutical companies,manufacturers,university researchers et al; as well as the reproductive medicine market,primarily in IVF and surrogacy; and the animal health market,primarily in the areas of vaccines and reproduction. Cryoport's proprietary Cryoport Express®Shippers,Cryoportal® Logistics Management Platform,leading-edge SmartPak II™ Condition Monitoring System and geo-sensing technology,paired with unparalleled cold chain logistics expertise and 24/7 client support,make Cryoport the end-to-end cold chain logistics partner that the industry trusts. Cryoport is dedicated to: simplifying global cold chain logistics through innovative technology,unmatched monitoring and data capture and support,including consulting; delivering the most advanced temperature-controlled logistics solutions for the life sciences industry; and providing vital information that provides peace of mind throughout the life of each logistics process.

For more information,visitwww.cryoport.com. Sign up to follow @cryoport on Twitteratwww.twitter.com/cryoport.

Forward Looking Statements

Statements in this news release which are not purely historical,including statements regarding Cryoport,Inc.'s intentions,hopes,beliefs,expectations,representations,projections,plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include,but are not limited to,risks and uncertainties associated with the effect of changing economic conditions,trends in the products markets,variations in the Company's cash flow,market acceptance risks,and technical development risks. The Company's business could be affected by a number of other factors,including the risk factors listed from time to time in the Company's SEC reports including,but not limited to,the Company's 10-K for the year ended December 31,2018 filed with the SEC. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport,Inc. disclaims any obligation,and does not undertake to update or revise any forward-looking statements in this press release.

Logo - http://cusmail.com/res/2023/07-23/20/9488d3fb7d0e6f0f8f2e2ed4cf1c414b.jpg